## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT	OF CHANGES	S IN BENEFIC	IAL OWNERS	HIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

4. N	A	Danastina Dan *						rker or Tradin			5.0	Relationship	of Reporting	n Dere	on(s) to les	uer	
1. Name and Address of Reporting Person* <u>Heyrman Reinilde</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol Bellerophon Therapeutics, Inc. [ BLPH ]						eck all appli Directo	cable)	y F C131	10% Ow			
(1.54) (Fire) (Middle)					Date of Earliest Transaction (Month/Day/Year)					$\dashv$	X Officer below)	(give title		Other (s below)	pecify		
(Last) (First) (Middle) C/O BELLEROPHON THERAPEUTICS, INC.					03/12/2015						Chi	ef Clinica	l Dev	. Officer			
53 FRONTAGE ROAD, SUITE 301				<u> </u>								C. Ladicidad an Asia (Corona Ellina (Charles III)					
(Street) HAMPTON NJ 08827				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)					Lin	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(SI	tate) (	(Zip)									Perso					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			ransaction e onth/Day/Ye	Execution Date,		Code (Ins	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)			Benefici	es For ally (D) Following (I) (	Form: (D) or	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
						Code V	Amount	(A) o (D)	r Price	Transac (Instr. 3	tion(s)			Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amount of Securities Underlying Derivative (Instr. 3 and		f g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e Owners s Form: Direct or Indi g (I) (Ins	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$10.22	03/12/2015		A		9,909		(1)	03/11/2025	Common Stock	9,909	\$0	9,909		D		

## **Explanation of Responses:**

1. This option vested as to 25% of the underlying shares on March 13, 2015 (the "Vesting Commencement Date") and vests as to an additional 25% of the underlying shares on each of the first, second and third anniversaries of the Vesting Commencement Date.

/s/ David Abrams, as Attorneyin-Fact for Reinilde Heyrman

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.